The forecasted use of peptic ulcer and gastro-oesophageal reflux diseases (GORD) medicines in Germany shows a steady and slight increase in defined daily dosage units per thousand persons per day from 2024 to 2028. Starting from a 2023 baseline, the values for 2024 onwards illustrate modest year-on-year variations of approximately 0.2 to 0.3%. The compound annual growth rate (CAGR) across this period remains small, suggesting slow but consistent growth in medicine usage.
Future trends to watch for include advancements in treatment options and potential shifts in public health policies that could impact prescription rates. Additionally, societal lifestyle changes may also affect the demand for these medications.
